Myeloid Clinical Trials

614 recruitingLast updated: June 18, 2026

There are 614 actively recruiting myeloid clinical trials across 56 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, New York, New York, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Myeloid Trials at a Glance

614 actively recruiting trials for myeloid are listed on ClinicalTrialsFinder across 6 cities in 56 countries. The largest study group is Phase 1 with 258 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running myeloid studies include M.D. Anderson Cancer Center, City of Hope Medical Center, and The First Affiliated Hospital of Soochow University.

Treatments under study

About Myeloid Clinical Trials

Looking for clinical trials for Myeloid? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myeloid trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myeloid clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 614 trials

Recruiting
Phase 2

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

Core Binding Factor Acute Myeloid Leukemia
National Cancer Institute (NCI)162 enrolled15 locationsNCT06917911
Recruiting
Phase 2

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Acute Myeloid LeukemiaAcute Myeloid Leukemia Post Cytotoxic TherapyAcute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm+1 more
National Cancer Institute (NCI)335 enrolled221 locationsNCT05554406
Recruiting
Phase 1

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaAcute Myeloid Leukemia With KMT2A Rearrangement+1 more
National Cancer Institute (NCI)38 enrolled22 locationsNCT05886049
Recruiting
Phase 2Phase 3

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Acute Myeloid Leukaemia (AML)
Moleculin Biotech, Inc.312 enrolled25 locationsNCT06788756
Recruiting
Phase 1

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaAcute Myeloid Leukemia Post Cytotoxic Therapy
National Cancer Institute (NCI)47 enrolled6 locationsNCT07012044
Recruiting
Phase 1

A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, Refractory
Memorial Sloan Kettering Cancer Center18 enrolled7 locationsNCT07011004
Recruiting
Phase 2

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia
National Cancer Institute (NCI)147 enrolled223 locationsNCT06317649
Recruiting
Phase 1Phase 2

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Acute Lymphoblastic LeukaemiaHigher Risk Myelodysplastic SyndromesAcute Myeloid Leukaemia
AstraZeneca84 enrolled30 locationsNCT07155226
Recruiting
Phase 2

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia
National Cancer Institute (NCI)153 enrolled178 locationsNCT05554393
Recruiting
Phase 1

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting

Familial Investigations of Childhood Cancer Predisposition

Pancreatic CancerHereditary Breast and Ovarian CancerHodgkin Lymphoma+43 more
St. Jude Children's Research Hospital1,500 enrolled1 locationNCT03050268
Recruiting
Phase 1

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

Acute Myeloid LeukemiaMyelodysplastic SyndromesMyeloproliferative Neoplasm+1 more
Dana-Farber Cancer Institute50 enrolled2 locationsNCT04024761
Recruiting
Phase 1

MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
City of Hope Medical Center12 enrolled1 locationNCT07025564
Recruiting
Phase 1

8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
City of Hope Medical Center30 enrolled1 locationNCT05263284
Recruiting
Phase 1

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

Acute Myeloid LeukemiaLeukemiaMyelodysplastic Syndromes+3 more
Dana-Farber Cancer Institute15 enrolled2 locationsNCT06138587
Recruiting
Phase 1

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Acute Myeloid LeukemiaMyelodysplastic SyndromeBlastic Plasmacytoid Dendritic Cell Neoplasm
Dana-Farber Cancer Institute72 enrolled3 locationsNCT03113643
Recruiting
Phase 2

Ivosidenib as Post-HSCT Maintenance for AML

Acute Myeloid Leukemia (AML)IDH1 MutationHematopoietic Stem Cell Transplant (HSCT)
Massachusetts General Hospital75 enrolled5 locationsNCT06707493
Recruiting
Phase 1Phase 2

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Hematopoietic and Lymphoid Cell NeoplasmAcute Myeloid Leukemia in RemissionChronic Myelomonocytic Leukemia+9 more
Fred Hutchinson Cancer Center30 enrolled1 locationNCT03670966
Recruiting
Phase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+2 more
National Cancer Institute (NCI)2,000 enrolled347 locationsNCT05564390
Recruiting

Individualized AML Treatment

Relapsed/Refractory Acute Myeloid Leukemia (AML)
City of Hope Medical Center18 enrolled1 locationNCT07613385